LLY — Eli Lilly and Company

The Street remains firmly constructive: as of 2026-09-13 the FMP ratings breakdown showed 33 Buy, 9 Hold and 3 Sell (consensus rating 'Buy'), with a consensus 12-month price target of $1,324.67 (high $1,500, low $940) and a 16-analyst recent average of $1,328.88 — implying roughly +19% upside from $1,115.25. That stance was reinforced by the 2026-08-05 Q2 print: revenue +47.7% YoY to $22.97B, non-GAAP EPS +33% YoY to $8.38, and a raised full-year revenue range of $85–87B (from $82–85B). The wobble is purely price action — LLY is -8.57% over one month and -2.93% over one week despite the beat-and-raise, which looks like profit-taking/rotation after a ~50% 12-month run rather than a change in fundamental narrative. Note the bull case is genuinely consensus, not contrarian: at 33 buys vs 3 sells there is very little scepticism priced in, which itself is a risk.

Revenue has compounded enormously and is still accelerating, not decelerating: $9.50B in Q3 2023 to $22.97B in Q2 2026, with YoY growth of +44.7% (Q4'24), +45.2% (Q1'25), +37.7% (Q2'25), +53.9% (Q3'25), +42.6% (Q4'25), +55.5% (Q1'26) and +47.7% (Q2'26) — seven straight quarters in the 38–55% band, with Q2'26 re-accelerating off the soft Q2'25 comp. Sequentially, Q2'26 rose +16.0% QoQ (vs +2.6% in Q1'26), the strongest sequential step in the dataset. Gross margin hit a record 85.8% in Q2'26 (vs 84.3% Q2'25, 82.9% Q3'25 and an anomalous 81.9% in Q1'26). The one soft line is GAAP operating margin: 39.1% in Q2'26 versus 45.8% in Q2'25 and 47.6% in Q3'25, reversing part of the 2024–25 expansion from ~31% to ~48%. That reversal is an accounting artifact, not operating deterioration — total non-R&D operating expense jumped from ~$2.65B in Q2'25 to ~$6.91B in Q2'26 (a ~$4.3B swing) while R&D only rose from $3.34B to $3.82B, consistent with acquired IPR&D charges from the Orna, Ajax and Centessa bolt-ons; non-GAAP EPS still grew 33% YoY. FCF is lumpy but large: $7.76B in Q2'26, $3.01B in Q1'26, $8.61B in Q3'25, $0.68B in Q4'25, for TTM FCF of ~$20.1B against ~$11.7B annualized capex. The balance sheet is where the growth is being financed: long-term debt climbed from $17.9B (Q3'23) to $47.9B (Q2'26) while equity rose from $11.2B to $33.9B. Net: structural acceleration in revenue and gross margin, one-off-driven noise in GAAP operating margin.

Neither cheap nor outrageous — 'fair, with a growth-justified premium.' As of 2026-09-13 the trailing P/E was 37.4 (on $29.93 TTM EPS) versus a 5-year average trailing P/E of 63.05, so on its own history the stock is genuinely de-rated. Forward P/E on next-FY consensus EPS of $36.392 is ~30.6x, against a street price target implying ~19% upside. The reported PEG of 0.396 is flattering because it uses the trailing growth rate, but even a conservative PEG of ~1.4–1.6 on ~22% forward EPS growth supports a 31–35x forward multiple — roughly where it trades. P/S of 13.18 is essentially in line with the 5-year average of 13.42. The problem is absolute: P/B 29.4, EV/EBITDA 29.6, price-to-cash-flow ~111, and an FCF yield of only ~1.9% ($20.1B TTM FCF on a $1.05T market cap) leave almost no valuation cushion if GLP-1 volume growth slows or pricing compresses. The deterministic model's own valuation overlay tags it 'Cheap vs. its own history' (score 76.1) while its ratio screener scores a weak 46.5 — both are right, from different angles.

The key tell as of 2026-09-13 is divergence: earnings estimates are going UP (Q2 beat, FY26 guide raised to $35.50–$36.50, next-FY consensus EPS $36.392) while the price is going SIDEWAYS-to-DOWN (-1.53% over 3 months, -8.57% over 1 month). That means the multiple, not the earnings, is doing the work — LLY is de-rating from 63x trailing toward 30.6x forward even as EPS compounds ~22%. Two ways to read it. Bull read: a 30.6x forward P/E for a business growing revenue ~48% with 85.8% gross margins and 30.2% ROIC is cheap, and when the multiple stops compressing the stock resumes tracking EPS upward — $36.39 of EPS at 34x is $1,237. Bear read: the market is pre-emptively repricing LLY as a maturing mega-cap because the law of large numbers bites — incremental tirzepatide growth eventually cannot outrun a trillion-dollar base, and the FY26 guide already absorbed IPR&D charges, meaning 'clean' EPS growth partly depends on how much M&A Lilly keeps doing. Practical takeaway: at $1,115.25 you are paying for continued 20%+ EPS delivery with multiple stability, NOT for an obvious mispricing. If you need a beat-and-raise every quarter to hold the multiple, the bar is high — and the guidance raise on 2026-08-05 was not enough to lift the shares.

As of 2026-09-13 the technical picture was a pullback inside a longer uptrend. RSI(14) stood at 35.43 — weak but not yet oversold (the classic 30 line). The stock was -5.70% below its 20-day SMA (~$1,183) and -5.82% below its 50-day SMA (~$1,184), but still +4.78% above its 200-day SMA (~$1,064). Returns: -2.93% over 1 week, -8.57% over 1 month, -1.53% over 3 months, +13.26% over 6 months. That profile says short-term downtrend, medium-term uptrend, and the 200-day near $1,064 is the level that matters — a break there would turn this from 'healthy pullback' into 'trend damage.' For entry timing, RSI near 35 with price mid-way between the 200-day and the 20/50-day cluster is a 'wait for stabilization' zone rather than a 'back up the truck' zone; a reclaim of ~$1,184 (the 20/50-day shelf) would be the cleaner confirmation, while a tag of the low-$1,060s with RSI holding above 30 would be the higher-probability value entry. Do not treat these as live levels — they are fixed to 2026-09-13 and will have moved by the time you read this.

• Incretin demand tailwinds: expanding payer access, including Medicare GLP-1 bridge programs covering millions of eligible seniors, is pulling volume into the category and directly benefits Mounjaro/Zepbound.
• US drug-pricing policy: IRA Medicare negotiation, PBM reform and rebate restructuring remain the single biggest exogenous threat to realized net price on high-cost biologics, even as volume growth currently masks it.
• Competitive intensity and manufacturing scale: Novo Nordisk plus emerging oral and next-gen incretins (including Amgen's and others' programs) are racing Lilly on capacity, formulation and price; Lilly's answer is capital-intensive — capex ran $2.93B in Q2 2026 alone and it committed another $4.5B to Indiana manufacturing.
• Tariffs and pharma supply-chain on-shoring policy: any tariff or MFN-style pricing action on imported APIs/finished doses would hit gross margin, which is why domestic capacity commitments are partly defensive.
• Rates and duration sensitivity: beta of 0.502 is low and revenue growth insulates LLY from macro, but a 30x-forward-earnings, 29x-book mega-cap remains structurally exposed to discount-rate moves and to growth-to-value rotation, which is a plausible partial explanation for the flat 3-month tape despite the beat.

• Retatrutide BLA submission planned for Q1 2027 (obesity, obstructive sleep apnea, knee osteoarthritis pain) — the bull camp's primary re-rating catalyst, on a Phase 3 package already described as robust.
• Investment Community Meeting on 2026-12-07 — a full corporate/pipeline update and the most likely venue for long-range guidance that could reset the multiple.
• Continued quarterly beat-and-raise cadence on Mounjaro/Zepbound volume plus the manufacturing capacity ramp, which is what has driven seven straight quarters of 38–55% YoY revenue growth.
• Further bolt-on M&A and regulatory wins — the recent pattern (Orna, Ajax, Centessa acquisitions; Ebglyss dosing approval; EU clearance for Jaypirca in CLL) shows Lilly is actively buying pipeline optionality, though each deal carries an IPR&D earnings drag in the quarter it closes.
• Expansion of payer coverage for obesity/diabetes indications, which would widen the addressable volume base beyond current Medicare bridge programs.

• Single-molecule concentration: the overwhelming majority of growth is tirzepatide (Mounjaro/Zepbound). A safety signal, durability-of-weight-loss disappointment, or share loss to a competitor would hit revenue, margins and multiple simultaneously.
• Pricing and reimbursement compression — IRA negotiation, PBM formulary exclusion and compounded/telehealth channels could drive net price down faster than volume rises, and at 85.8% gross margin even modest price erosion sends a loud signal.
• Balance-sheet build-out without a demand guarantee: long-term debt has gone from $17.9B (Q3 2023) to $47.9B (Q2 2026) and capex is annualizing above $11B. If incretin demand undershoots the capacity being built, ROIC (currently 30.2%) and FCF conversion ($20.1B TTM, a ~1.9% FCF yield) deteriorate at exactly the wrong moment.
• Valuation has no cushion: 29.4x book, 29.6x EV/EBITDA, ~111x cash flow. Utility-like safety this is not — a growth deceleration from 48% to, say, 25% would compress the multiple hard even though 25% would still be excellent for pharma.
• Pipeline/execution risk on retatrutide and the broader late-stage book — the Q1 2027 BLA is now a priced-in expectation, so a delay or a label that excludes one of the three indications (OSA, knee OA) is a downside catalyst rather than a neutral event.
• Earnings quality optics: GAAP operating margin fell from 45.8% to 39.1% YoY in Q2 2026 because of acquired IPR&D charges. If Lilly keeps acquiring, GAAP EPS will keep running behind non-GAAP, and the gap is a legitimate thing for a skeptical investor to monitor.

This is a genuinely exceptional business trading at a fair-but-not-cheap price, and the honest answer as of 2026-09-13 is 'own it if you already do, add on weakness rather than chase strength.' The fundamentals are close to best-in-class — revenue +47.7% YoY, record 85.8% gross margin, 30.2% ROIC, -2.53% accruals ratio (cash earnings running ahead of reported earnings), $20.1B TTM free cash flow and a raised FY26 guide — and the forward P/E of ~30.6x is less than half the 5-year average trailing P/E of 63.05. What stops me from being outright bullish is that the score's 'Fair Fundamentals' band is doing real work: at 29.4x book, 29.6x EV/EBITDA and a 1.9% FCF yield, the stock discounts flawless execution, the entire growth story rests on one molecule, and long-term debt has nearly tripled in three years to fund capacity that isn't yet proven to be needed. The 8.57% one-month drawdown with RSI at 35.43 is a constructive setup for a patient buyer, not a fire sale. Treat LLY as a core compounder to accumulate on the $1,060–$1,080 area (200-day support) rather than a value opportunity at $1,115.

I applied a 34x forward P/E to the next-FY consensus EPS of $36.392, giving $1,237. That 34x is a ~1.55 PEG on ~22% forward EPS growth, sits below the 5-year average trailing P/E of 63.05 (which is distorted by the low-earnings 2023–24 charge years), and is a modest re-rating from the 30.6x the stock traded at on 2026-09-13. I cross-checked it with an enterprise-value approach: next-FY consensus revenue of $88.25B at a ~49% EBITDA margin implies ~$43B of forward EBITDA; 28x that (a slight discount to the 29.6x TTM multiple) gives an EV of ~$1,210B, less ~$46B of net debt ($54.9B total debt against $8.9B cash) is ~$1,164B of equity, or ~$1,236 per share on ~942M shares — essentially identical to the P/E-derived figure, so I used $1,237. That is ~+11% from $1,115.25 and below the $1,324.67 street consensus, reflecting my more conservative view on multiple stability, single-molecule concentration, and the debt-funded capex cycle.